Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)
Brief Summary: Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab; Assigned to Arm(s): 2
B: Arm Label: Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q2W (Part B); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): MEL: Pembrolizumab 10 mg/kg Q2W (Part B), MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D), MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D), NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F), NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F), NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled), Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1), Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)
C: Arm Label: Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Durvalumab | Arm Label: Control Arm: Chemotherapy, then Observation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chemotherapy | Arm Label: Control Arm: Ipilimumab and Nivolumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ipilimumab and Nivolumab | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance | Intervention Type: DRUG; Name: Standard Chemotherapy; Assigned to Arm(s): Control Arm: Chemotherapy, then Observation | Intervention Type: DRUG; Name: Ipilimumab and Nivolumab; Assigned to Arm(s): Control Arm: Ipilimumab and Nivolumab
D: Arm Label: Surgery; Type: EXPERIMENTAL; Interventions: Procedure: (Extended) pleurectomy decortication | Arm Label: no surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: (Extended) pleurectomy decortication; Assigned to Arm(s): Surgery

Answer: A